Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) announced new preclinical data for votucalis, a novel broad-acting antihistamine, which shows promise in treating pain and itch linked to conditions like atopic dermatitis and psoriasis. The data, published in Frontiers in Pharmacology, highlight votucalis's ability to inhibit all four histamine GPCRs, offering new treatment avenues not available with current antihistamines. The research indicates votucalis achieves effective local administration at lower doses, potentially reducing CNS-related side effects typical of opioids.
Akari Therapeutics has secured approximately $9.0 million through definitive agreements with institutional and accredited investors, including Chairman Dr. Ray Prudo. The company will issue roughly 7,500,000 American Depository Shares (ADSs) at $1.20 per ADS, accompanied by warrants for additional shares. The offering is expected to close around March 10, 2022, pending customary conditions. This offering is registered under an effective shelf registration statement with the SEC, aiming to bolster Akari's financial position for development of its drug candidate, Nomacopan.
Akari Therapeutics has appointed Rachelle Jacques as President and CEO, effective end of March 2022. Jacques brings extensive experience in biotechnology, particularly in complement (C5) therapies, having previously served as CEO at Enzyvant Therapeutics and held significant roles at Alexion Pharmaceuticals. She is set to enhance the company's Phase 3 pipeline and drive commercialization efforts for nomacopan, a drug targeting rare diseases. Outgoing CEO Clive Richardson will support this transition.
Akari Therapeutics (Nasdaq: AKTX) announced promising results for its complement and leukotriene inhibitor, nomacopan, which improved survival rates in a preclinical trauma model from 30% to 80%. Funded by the U.S. Army's DoD, the findings suggest nomacopan's potential as a treatment for traumatic hemorrhage, addressing both military and civilian needs. The company plans further studies, including a collaboration for a UK observational study on traumatic brain injury. Nomacopan targets critical inflammatory pathways, making it viable for early intervention in severe trauma cases.
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company, announced that CEO Clive Richardson will present at the BIO CEO & Investor Conference on February 15, 2022, at 2:30 p.m. ET in New York. The presentation will focus on Akari's innovative therapies targeting orphan autoimmune diseases and will be available live and on-demand for registered participants. The Company is developing Nomacopan, a C5 complement inhibitor, for conditions like bullous pemphigoid and thrombotic microangiopathy. Investors are encouraged to arrange meetings with management during the conference.
Akari Therapeutics (Nasdaq: AKTX) announced the development of an inhaled delivery system for its drug nomacopan, targeting orphan autoimmune and inflammatory diseases. Collaborating with Inhalation Sciences AB, Akari aims to enhance dosing and pharmacokinetics for both dry powder and nebulized forms. CEO Clive Richardson emphasized the potential of nomacopan in treating exacerbations in lung diseases like COPD and severe asthma by targeting complement C5 and leukotriene pathways. Observational studies show elevated levels of C5 and LTB4 in exacerbating conditions, supporting nomacopan's therapeutic potential.
Akari Therapeutics announced the FDA's approval of a new manufacturing process for its lead drug candidate, nomacopan, enhancing yield by at least 5-fold. This advancement significantly reduces the cost of goods for ongoing clinical studies and future commercialization. Nomacopan is currently in two Phase III clinical programs targeting conditions like bullous pemphigoid and thrombotic microangiopathy. This milestone marks a pivotal step towards bringing nomacopan to market, following years of development and collaboration with manufacturing partners.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced that CEO Clive Richardson will present a company overview at the H.C. Wainwright BioConnect Conference, taking place virtually from January 10-13, 2022. The pre-recorded presentation will be accessible on-demand starting January 10, 2022, at 7:00 a.m. ET on the company’s website. Akari focuses on innovative therapeutics for rare autoimmune diseases, with its leading drug candidate Nomacopan targeting conditions influenced by complement and leukotriene systems.
Akari Therapeutics (Nasdaq: AKTX) announced a registered direct offering to raise approximately $6.0 million. The company will issue approximately 4,310,839 American Depository Shares (ADSs) at $1.40 per ADS, along with warrants for one-half ADS at an exercise price of $1.65. The offering is expected to close around January 4, 2022, pending customary conditions. Akari focuses on developing treatments for autoimmune and inflammatory diseases, with its lead drug candidate nomacopan currently in clinical evaluation for various conditions.
Akari Therapeutics (NASDAQ: AKTX) reported progress in its clinical programs for nomacopan, focusing on treatments for severe autoimmune conditions, including bullous pemphigoid and pediatric HSCT-TMA. The Phase III studies are now enrolling patients, with FDA designations as Orphan Drug and Fast Track. Financially, as of September 30, 2021, the company had $13.4 million in cash and reported a net loss of approximately $1.5 million for Q3 2021, compared to a net income of around $0.9 million in Q3 2020. R&D income also declined significantly to $0.4 million.